Vertex Pharma (VRTX): VX-661/Kalydeco Combo Fails But Was A Long Shot - Baird
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- Target (TGT) November/December Comps Fell 1.3%; Lowers Guidance
- US Drone Market Could Reach 6 Million By 2019 - Oppenheimer
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- United Airlines (UAL) Tops Q4 EPS by 5c
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Vertex (NASDAQ: VRTX) as the company followed in Orkambi's footsteps when the VX-661/ivacaftor failed to show a benefit in patients heterozygous for the F508del mutation and a mutation resulting in minimal CFTR function (F508del het/mins).
The analyst had been skeptical from the start, but the next-gen triple combos are expected to move into Phase 2 soon. This is an effort the analyst is far more enthusiastic about for this subgroup of CF patients.
No change to the price target of $128.
Shares of Vertex closed at $102.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Starts Bruker (BRKR) at Hold
- Credit Suisse Downgrades J. C. Penney (JCP) to Underperform, Says Limited Topline Opportunities Delay Turnaround
- Credit Suisse Upgrades Nordstrom (JWN) to Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!